Trial Profile
An Open-label Study to Assess Brain Uptake and Safety of AH110690 (18F) Injection in Subjects With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2021
Price :
$35
*
At a glance
- Drugs Flutemetamol-F-18 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Diagnostic use
- Sponsors GE Healthcare
- 14 Nov 2014 New trial record